Your SlideShare is downloading. ×
Psoriatic Arthritis - Pipeline Review, H1 2014: Industry Overview
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Psoriatic Arthritis - Pipeline Review, H1 2014: Industry Overview


Published on

Psoriatic Arthritis - Pipeline Review, H1 2014 @ …

Psoriatic Arthritis - Pipeline Review, H1 2014 @

This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Psoriatic Arthritis - Pipeline Review, H1 2014 Psoriatic Arthritis - Pipeline Review, H1 2014 Summary Global Markets Directs, Psoriatic Arthritis - Pipeline Review, H1 2014, provides an overview of the Psoriatic Arthritiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 8 list Of Figures 9 introduction 10 global Markets Direct Report Coverage 10 psoriatic Arthritis Overview 11 therapeutics Development 12 pipeline Products For Psoriatic Arthritis - Overview 12 pipeline Products For Psoriatic Arthritis - Comparative Analysis 13 psoriatic Arthritis - Therapeutics Under Development By Companies 14 psoriatic Arthritis - Pipeline Products Glance 17 late Stage Products 17 clinical Stage Products 18 early Stage Products 19 Psoriatic Arthritis - Pipeline Review, H1 2014
  • 2. unknown Stage Products 20 psoriatic Arthritis - Products Under Development By Companies 21 psoriatic Arthritis - Companies Involved In Therapeutics Development 23 alcon, Inc. 23 bristol-myers Squibb Company 24 amgen Inc. 25 eli Lilly And Company 26 celltrion, Inc. 27 biocon Limited 28 pfizer Inc. 29 ucb S.a. 30 sandoz Inc. 31 celgene Corporation 32 swedish Orphan Biovitrum Ab 33 panacea Biotec Limited 34 viropro Inc. 35 alder Biopharmaceuticals Inc. 36 coronado Biosciences, Inc. 37 kineta, Inc. 38 avesthagen Limited 39 covagen Ag 40 shanghai Celgen Bio-pharmaceutical Co., Ltd. 41 biosidus S.a. 42 genor Biopharma Co., Ltd. 43 forward Pharma A/s 44 inbiopro Solutions Pvt. Ltd. 45 innovent Biologics, Inc. 46 epirus Biopharmaceuticals, Inc. 47 alphamab Co., Ltd 48 pharmapraxis 49 psoriatic Arthritis - Therapeutics Assessment 50 assessment By Monotherapy Products 50 assessment By Target 51 assessment By Mechanism Of Action 54 assessment By Route Of Administration 57 assessment By Molecule Type 59 drug Profiles 61 apremilast - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 secukinumab - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 certolizumab Pegol - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 infliximab Biosimilar - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 infliximab Biosimilar - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 brodalumab - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 ixekizumab - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 tofacitinib - Drug Profile 78 product Description 78 mechanism Of Action 78 Psoriatic Arthritis - Pipeline Review, H1 2014
  • 3. r&d Progress 78 secukinumab - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 abatacept - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 infliximab Biosimilar - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 adalimumab Biosimilar - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 clazakizumab - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 dimethyl Fumarate - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 shk-186 - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 infliximab Biosimilar - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 adalimumab Biosimilar - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 adalimumab Biosimilar - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 itolizumab - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 tso - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 etanercept Biosimilar - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 adalimumab Biosimilar - Drug Profile 103 product Description 103 mechanism Of Action 103 r&d Progress 103 etanercept Biosimilar - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 ibpm-005-ix - Drug Profile 105 product Description 105 mechanism Of Action 105 r&d Progress 105 ibpm-004-am - Drug Profile 106 product Description 106 mechanism Of Action 106 Psoriatic Arthritis - Pipeline Review, H1 2014
  • 4. r&d Progress 106 etanercept Biosimilar - Drug Profile 107 product Description 107 mechanism Of Action 107 r&d Progress 107 cova-322 - Drug Profile 108 product Description 108 mechanism Of Action 108 r&d Progress 108 etanercept Biosimilar - Drug Profile 109 product Description 109 mechanism Of Action 109 r&d Progress 109 adalimumab Biosimilar - Drug Profile 110 product Description 110 mechanism Of Action 110 r&d Progress 110 etanercept Biosimilar - Drug Profile 111 product Description 111 mechanism Of Action 111 r&d Progress 111 adalimumab Biosimilar - Drug Profile 112 product Description 112 mechanism Of Action 112 r&d Progress 112 ibi-303 - Drug Profile 113 product Description 113 mechanism Of Action 113 r&d Progress 113 nd-007 - Drug Profile 114 product Description 114 mechanism Of Action 114 r&d Progress 114 infliximab Biosimilar - Drug Profile 115 product Description 115 mechanism Of Action 115 r&d Progress 115 etanercept Biosimilar - Drug Profile 116 product Description 116 mechanism Of Action 116 r&d Progress 116 adalimumab Biosimilar - Drug Profile 117 product Description 117 mechanism Of Action 117 r&d Progress 117 inv-17 - Drug Profile 118 product Description 118 mechanism Of Action 118 r&d Progress 118 anakinra - Drug Profile 119 product Description 119 mechanism Of Action 119 r&d Progress 119 adalimumab Biosimilar - Drug Profile 120 product Description 120 mechanism Of Action 120 r&d Progress 120 infliximab Biosmiliar - Drug Profile 121 product Description 121 mechanism Of Action 121 r&d Progress 121 etanercept Biosimilar - Drug Profile 122 product Description 122 mechanism Of Action 122 r&d Progress 122 etanercept Biosimilar - Drug Profile 123 product Description 123 mechanism Of Action 123 Psoriatic Arthritis - Pipeline Review, H1 2014
  • 5. r&d Progress 123 psoriatic Arthritis - Recent Pipeline Updates 124 psoriatic Arthritis - Dormant Projects 162 psoriatic Arthritis - Discontinued Products 163 psoriatic Arthritis - Product Development Milestones 164 featured News & Press Releases 164 jan 22, 2014: Stelara (ustekinumab) Receives Health Canada Approval For Treatment Of Active Psoriatic Arthritis 164 oct 29, 2013: Oral Apremilast Monotherapy Demonstrated Long-term Clinical Benefits In Psoriatic Arthritis Patients Nave To Previous Dmard Therapy 165 oct 28, 2013: Oral Apremilast Demonstrated Clinically Meaningful And Statistically Significant Improvements In Enthesitis And Dactylitis 166 oct 28, 2013: New Stelara Data Show Inhibition Of Joint Destruction In Patients With Active Psoriatic Arthritis 168 oct 25, 2013: Ucb-sponsored Data On Cimzia To Be Highlighted At 2013 American College Of Rheumatology Annual Scientific Meeting 171 oct 24, 2013: Chmp Adopts Positive Opinion For Ucb Pharma's Cimzia 173 sep 30, 2013: Cimzia Approved By The U.s. Fda For Treatment Of Adult Patients With Active Psoriatic Arthritis 174 sep 26, 2013: New Long-term Apremilast Data To Be Presented At American College Of Rheumatology Annual Meeting 175 sep 23, 2013: Stelara (ustekinumab) Receives Fda Approval To Treat Active Psoriatic Arthritis 178 sep 23, 2013: Stelara Receives European Commission Approval For Treatment Of Active Psoriatic Arthritis 179 appendix 182 methodology 182 coverage 182 secondary Research 182 primary Research 182 expert Panel Validation 182 contact Us 183 disclaimer 183 ResearchMoz( is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: Website: Psoriatic Arthritis - Pipeline Review, H1 2014